5911results about How to "Inhibit growth" patented technology

A heat treatment jig for supporting silicon semiconductor substrates by contacting, being loaded onto a heat treatment boat in a vertical heat treatment furnace, comprises; the configuration of a ring or a disc structure with the wall thickness between 1.5 and 6.0 mm; the deflection displacement of 100 μm or less at contact region in loaded condition; the outer diameter which is 65% or more of the diameter of said substrate; and the surface roughness (Ra) of between 1.0 and 100 μm at the contact region. The use of said jig enables to effectively retard the slip generation and to avoid the growth hindrance of thermally oxidized film at the back surface of said substrate, diminishing the surface steps causing the defocus in photolithography step in device fabrication process, thereby enabling to maintain high quality of silicon semiconductor substrates and to substantially enhance the device yield.

A heat treatment jig for supporting silicon semiconductor substrates by contacting, being loaded onto a heat treatment boat in a vertical heat treatment furnace, comprises; the configuration of a ring or a disc structure with the wall thickness between 1.5 and 6.0 mm; the deflection displacement of 100 μm or less at contact region in loaded condition; the outer diameter which is 65% or more of the diameter of said substrate; and the surface roughness (Ra) of between 1.0 and 100 μm at the contact region. The use of said jig enables to effectively retard the slip generation and to avoid the growth hindrance of thermally oxidized film at the back surface of said substrate, diminishing the surface steps causing the defocus in photolithography step in device fabrication process, thereby enabling to maintain high quality of silicon semiconductor substrates and to substantially enhance the device yield.

Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

An activatable (e.g., heat expandable) material and articles incorporating the same is disclosed. The material includes an epoxy resin; an epoxy / elastomer hybrid or reaction product; a blowing agent; a curing agent; and optionally, a filler. In preferred embodiments, the material includes aramid fiber, nanoclay or both.

The present invention relates to the isolation and characterization of nucleotide sequences encoding novel insecticidal proteins secreted into the extracellular space from Bacillus thuringiensis and related strains. The proteins are isolated from culture supernatants of Bacillus thuringiensis and related strains and display insecticidal activity against coleopteran insects including Colorado potato beetle (Lymantria dispar) and Southern Corn Rootworm (Diabrotica undecempunctata). Insecticidal proteins encoded by nucleotide sequences that hybridize to the isolated and characterized nucleotide sequences are disclosed. Also disclosed are methods of making and using transgenic cells and plants comprising the novel nucleotide sequence of the invention.

The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.

Methods for preventing or treating an IgE-mediated allergic disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

A biofilm penetrating composition for coating medical devices for substantially preventing the growth or proliferation of biofilm embedded microorganisms on at least one surface of the medical device is disclosed. A biofilm penetrating composition solution for cleaning medical devices which is capable of substantially removing all of the biofilm embedded microorganisms from at least one surface of medical devices is also disclosed. The biofilm penetrating composition coating and solution include a biofilm penetrating agent and may also include a base material. Medical devices coated with the biofilm penetrating composition and methods for coating medical devices and methods for removing biofilm embedded microorganisms from at least one surface of the medical devices are also disclosed.

The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and / or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and / or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

The present invention relates to oil-in-water mascara compositions comprising water-insoluble polymeric materials in the form of an aqueous emulsion, water-soluble, film-forming polymers and organophilic clays. Said compositions exhibit improved wear and are removable with soap and water.

The invention relates to polymers with antimicrobial properties, consisting of: a) 99-40 wt % non functional vinylically polymerizable monomers and b) 1-60 wt % functional vinylically polymerizable monomers of general formula (I) wherein V=vinyl, (meth)acroyl, allyl or styryl, A=a possibly available linking unit, which can be alkyl, aryl, arylalkyl or hydroxy alkyl, which can also be interrupted by hetero atoms, e.g. by hetero atoms in urethane, carbonate, ester, amide or ether groups, wherein y=0 or is 1, Hsp=a hydrophilic spacer of general formula (i) -(O-CH2-CH2)r- and / or (ii) -(O-CH2-CH(CH3))s with r=0-40, s=0-40 and r+s=2-40, also m=1.2 or 3 and R1=CH3, ethyl or benzyl, R2=an alkyl radical with 8-20 C-atoms, wherein t=1, 2 or 3 and X-=Cl-, Br-, I- or alkyl sulphate.

Provided is an oriented multilayer porous film comprising at least one layer comprising: a heat, solvent, and degradation resistant matrix polymer; a plurality of interconnecting pores; and a porosity less than 90%. The film is made by a dry and / or wet method, with its multilayer structure constructed by coextrusion, lamination, and coating. The film of this disclosure finds a wide range of applications as a permselective medium for use in energy harvesting and storage, filtration, separation and purification of gases and fluids, CO2 and volatile capture, electronics, devices, structural supports, packaging, labeling, printing, clothing, drug delivery systems, bioreactor, and the like. The film is preferably used as a separator of lithium-ion, lithium-sulfur, lithium-air, metal-air, and nonaqueous electrolyte batteries.

In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.

The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). One chain of a heterodimer comprises a binding domain that specifically binds a target (e.g., a receptor). In addition, both chains of a heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in reducing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.

The present invention generally relates to articles of manufacture, such as medical devices, having a non-fouling surface comprising a grafted polymer material. The surface resists the adhesion of biological material.

Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of such cancers. Additionally, the invention provides a method of increasing the cytotoxicity of forms of Pseudomonas exotoxin A (“PE”) with the mutation of a single amino acid, as well as compositions of such mutated PEs, nucleic acids encoding them, and methods for using the mutated PEs.

The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

Methods and devices arising from the practice thereof for making and using battery electrodes formed onto ion permeable, electrically non-conductive substrates, preferably battery separators are disclosed herein. Electrodes are formed onto substrates using a variety of methods including, but not limited to, spray coating and electrophoretic deposition. Electrically conductive layers may be applied to the electrode coating layer side opposite or adjacent to the substrate to act as current collectors for the battery. Multilayer devices having alternating layers of conductive layers, electrode layers and substrates, wherein the conductive layers may be in electrical communication with other conductive layers to form a battery.

A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.

The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

The invention belongs to the field of titanium-based alloys, and particularly relates to a novel heat-resisting titanium alloy and a processing and manufacturing method and application thereof. The processing and manufacturing method comprises the composition elements of alloy components, smelting, heat processing, heat treatment and the like, wherein the alloy components are as follows (in percentage by weight): 5.4%-6.3% of Al, 3.0%-5.0% of Sn, 2.5%-6.4% of Zr, 0.0%-0.96% of Mo, 0.25%-0.5% of Si, 0.2%-0.5% of Nb, 0.3%-3.4% of Ta, 0.2%-1.6% of W, 0.0%-0.07% of C, less than or equal to 0.17% of O, less than or equal to 0.03% of Fe and the balance of Ti and inevitable impurity elements. The novel heat-resisting titanium alloy disclosed by the invention can obtain different matching of tensile strength, plasticity, permanence, creep strength and heat stability through the combination of different heat processing process and heat treatment processes, can be used for manufacturing parts, namely blades, coil assemblies and the like which are positioned on the high-temperature parts of an advanced aircraft engine, is used for a long time within a range of 600-650 DEG C, can also be used for manufacturing high temperature-resistant structural members, namely aerospace craft skin and the like, is used for a short time at about 700 DEG C and can be used as a material and the like used for high temperature-resistant corrosion-resistant valves of an automobile and a boiler.

A photocatalytically active titanium dioxide film may be applied onto surfaces of a variety of objects to oxidize matter that comes into contact with those surfaces. Various methods may be used to apply a solution of the photocatalytically active nanoparticles onto surfaces receiving regular human contact or proximate to human presence. An inorganic primer layer may be initially applied to an organic substrate, such as food, plants, flowers and foliage, to prevent the photocatalytically active coating from oxidizing the organic substrate.

The present invention relates to methods and compositions for the cryopreservation of pluripotent cells in general and human embryonic stem (ES) cells in particular. The stem cells are grown on a bottom layer of solid support matrix and subsequently covered by a top layer of solid support matrix forming a matrix-cell-matrix composition, to which an effective amount of cryopreservation media is added, prior to freezing. The methods of the invention yield cryopreserved cells that exhibit an increase in cell viability and a decrease in cell differentiation, facilitating storage, shipping and handling of embryonic stem cell stocks and lines for research and therapeutics.

A composition described wherein bismuth is chelated by a complexing agent such as a pyrithione or certain other thiol compounds in the form a metal:complexing agent complex. Methods for using the composition as a bacteriocidal, bacteriostatic, antibiofilm, antifungal, and antiviral agent and as a disinfectant and preservative are also provided.

The invention discloses a preparation method of laser forming nano particle reinforced aluminum-based composite material, belonging to the technical field of particle reinforced aluminum-based composite materials. The method comprises the steps of: (1) selecting SiC powder with purity of more than 99.9% and granularity of 40-60 nanometers, and AlSi10Mg powder with purity of more than 99.9% and granularity of 15-30 micrometers; (2) mixing the powders, wherein the weight of the SiC powder is 3%-10% of the total weight of the mixed powder; (3) putting the mixed powder into a planetary high-energy ball mill for milling; (4) taking the milled powder for SLM forming; and (5) repeating the step (4) until a three-dimensional block sample is completed. According to the method provided by the invention, the aluminum-based composite material with uniform microscopic structures can be prepared.

The invention provides an organic light-emitting diode display panel and a display. A protection layer additionally disposed on an inorganic layer on a retaining wall is used to prevent an inorganic layer crack from continuously growing, and therefore product sealing performance is improved, and product bending performance is improved. The organic light-emitting diode comprises a display area and an adjacent peripheral area. The display panel comprises a substrate, a display function layer, and a packaging layer. The display area comprises a display function layer, and the peripheral area comprises a first retaining wall, which is disposed around the display area. The packaging layer comprises at least one inorganic layer, which is vertical to the direction of the substrate, and is used to cover the first retaining wall. The display panel comprises the protection layer, which is vertical to the direction of the substrate, and is used to cover the at least one inorganic layer on the upper part of the first retaining wall.

Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.

All or a portion of a surface of an implantable sensor is covered with a biocompatible coating formed at least partially of a biomaterial matrix having properties that promote a substantially even growth of tissue cells over the surface of the coating. Additional materials, such as growth factors, agents that recruit endogenous stem cells, and cell adhesion motif arginine, glycine, aspartic acid may be included in the coating. Autologous cells may be added to the coating prior to implantation. The sensor surface may also be textured, by etching or abrading, in order to promote even tissue growth. Alternatively, the sensor surface may be covered with a coating having properties that inhibit the growth of tissue. These coatings may include a biomaterial, a biomaterial matrix having a drug, such as a sirolimus or a steroid, an active component, or a self assembled monolayer.